April 14, 2026
WoW. The new technologies seem to be stepping up more rapidly than effort. Now it’s a bi-specific genetically engineer material designed to capture a T-cell in a human’s body on one side, and on the other side, has something to capture a PCa cell, essentially dragging the T-cell over to the selected PCa cell so it can kill it. Here is a summary.
Yet another technology, Bispecific T-Cell engager technology for PCa initiates Phase 3 trials
Xaluritamig (AMG 509): a Phase 3 registration trial (NCT06691984) is underway. This is a STEAP1-targeting BiTE. Following positive Phase 1 results (PSA50 response in 49% of patients).
Bi-specific T-Cell Engagers are bits of genetic material that bind to tumor-associated antigens on cancer cells on one part of their construct and the CD3 receptor on T-cells on another part, enabling T-cells to destroy tumors.
I am fighting my way though the cited research paper. It’s seems tougher than usual, either because I am running out of gas a little with learning about all these new technologies one after another, or that it’s not as closely related to my current body of knowledge. I will try to bring more clarity as we move forward,
Best of Great Science for Everyone !
I’m out for tonight, in 9 hours I leave for a 24 hour sojourn back to NJ. Wish me luck.
April 9, 2026
“Something is Materially Different Right Now.” That is how Dr. Marson spoke about the state of the art in medicine, about disease cures, and prostate cancer cures in particular.
I just finished transcribing about 3 minutes more of Dr. Marson’s discussion with Dr. Huberman on the Huberman Lab Podcast. I find what is happening is truly amazing, although somewhat expected because I have a pretty good understanding of CRISPR technology and how revolutionary it is, having been discovered in 2012, and now in 2026 has worked it’s way into not only cancer research, but into successful trials in some cancer treatments. If you have not idea what CRISPR is or for some reason do not yet believe it is the most amazing discovery in our lifetimes and perhaps another lifetime or two, please review this video here. It requires no previous knowledge. I also include a second video from a few years back that explains some of the details of how CRISPR works as well as some of the revolutionary accomplishments that occurred in a very short period of time.
Here is the link to the new transcription of the section of the interview I call “Something is Materially Different Right Now.”
April 3, 2026
While reviewing things, I learned that want to mention I am taking Black Seed Oil for my arthritic knee, and I added Grape Seed Oil for its anti-PCa powers. Finally, I purchased some avocado oil for cooking after hearing Dr. Huberman talk about not wanting to eat charred meats. I extended that to my fried tofu. Avocado oil has a much higher smoke point and therefore I believe it’s not creating those bad things in the fry pan.
April 2, 2026
What a pain as I transcribe the first two minutes of the Huberman Lab interview with Dr. Marson. But it was worth it, as I took in the importance these words meant to me.
It’s especially inspiring to me, because what they are saying confirms what I have been learning about over the last two years about PCa, as well as my leveraging of my several years of research experience with protein enzymes. In my protein enzyme lab, our team discovered that Leucyl aminopeptidase cannot be solely relied upon to tell the protein enzyme story. Beyond that, I got exposure of what works and does not work in the research lab, and how truly distant pure research is from development into something useful in every-day life.
Two voices of authority, Mr. Marson and Dr. Huberman, have been brought into my conversation about what is possible. What is absolutely cool about it goes to how recent the podcast is, March 9, 2026, and having a pinnacle if not the pinnacle authority in Dr. Marson with respect to cancer immunology and CAR T-cell research and development.
Dr. Huberman’s research with respect to injecting large bits of DNA into cells by one of his graduate students through an electrical process not-well-understood-but-it-works technology gets a chuckle out of both men, as they somewhat casually, yet profoundly discuss the relative lighting speed with which current breakthroughs are occuring.
I can tell, and I hope you can tell, how amazed both men are at what is getting accomplished as they speak. And I appreciate the thoughtfulness that Dr. Marson puts into the words he speaks.
mRNA, CRISPR, CAR T-cell, and RLT PCa Therapies
Which will come to the rescue first? I put my money on CAR T-cell because they seem to be currently in the lead with respect to technologies doing the least collateral damage.
April 1, 2026
Welcome to April Fools Day, 2026. There will be no foolishness here, however. Perhaps I will allow some level of excitement after a few months of relative quiet, steady-as-she-goes behavior. That steady-state of nothing new continued through the middle of March, when I first hit upon the Nature article on advances in PCa therapies via mRNA genetic solutions.
Since I already thought I understood something about the founding technology behind mRNA-constructed solutions — CRISPR, I took a backwards dive into what CRISPR is and what it can do.
Then, in an effort to understand the relationship between CRISPR and mRNA-vaccines, I learned they are different technologies, and that while mRNA vaccines do not use CRISPR, they share a common foundation in lipid nanoparticle (LNP) delivery technology, which transports the nucleic acids into cells.
Most recently, CAR T-cell reprogramming started appearing in my searches, and I began looking at that and created this post, which I also put out on a social media site or two, to inform others.
Lo-and-Behold, I get a comment from a social media contributor with what I consider a Block Buster link to a video interview, one physician researcher interviewing another. The featured guest was Dr. Marson, who appears to be the Father of CAR T-cell reprogramming therapy. I say this, because he was able to get an audience with Dr. Jennifer Doudna, the Nobel Prize winner for her contributions to CRISPR technology. Dr. Marson also talked Dr. Doudna into working with him to discover how to use CRISPR technology to more precisely enhance CAR T-cell reprogramming. While there is a lot to this two and a half hour video, I drilled down on the conversation around how all this specifically applies to PCa. Not withstanding the jump ahead to that section, I find it useful to understand how knowledge progresses as revealed in the video that preceded this section. It is especially useful when estimating timeframes into the future when things might occur. I hope to get back to it.
In the video interview, Dr. Marson mentioned the forming of Arsenal Biosciences, and that Arsenal started its third Trial in PCa solid tumor studies. Since it’s been my recently acquired long term objective to get into a trial study, this caught my attention. So my research progressed into Arsenal Biosciences, and what I am learning is pretty amazing.
The two previous trials are AB 1015 NCT 05617755 and AB 2100 NCT O6245917.
The third trial, AB 3028, is a Phase 1/2 study. NCT 07285694. It is completing or has completed its patient selection and expect to apply for Investigational New Drug (IND) status. The Primary Completion Date: May 2029, Final Completion in May 2031. Broad availability may occur in the 2031 – 2033 time-frame.
Dr. Marson speculates that a wider use of this technology could be available to everyone with PCa, even low-risk patients, by 2035. A closer examination of the Arsenal website shows AB4000, and AB 7000 are in the works, one in collaboration with Bristol Meyers Squibb (BMS).
And so with CAR T-cell reprogramming solutions at top-of-mind, I have awareness that there are also mRNA solutions in the pipeline, as well as Ligand-based solutions in Stage 3 trials. What am I to do? What actions should I be taking to make the most of this multi-pathed PCa explosion of research trials?
What’s next that’s best for me?
Keep doing what I am doing:
- Diet – Plant-Based. Vegan when possible. Everything fresh as possible. Try to continue to drop weight.
- Excercise – weight lifting in the gym, and cardio for heart and circulation.
- Supplements – Keep up Anti-PCa Strategies
- PSO – Pomegranate Seed Oil Strategy
- Ursolic Acid Strategy
- Apigenin Strategy
- Finely Ground Black Pepper for the Piperine
- See them all at the link above
- Every-Day Morning Routine & More
- At My Counter every day consumption of non-pill-oriented supplements
- Buying and Creating easy to use pill-oriented supplements for each day and night.
Leave a Reply